Covid Vaccines Increase Menstrual Bleeding Risk by Up to 41%, BMJ Study Finds – But the Authors Downplay it

I have previously written about a tendency by medical study authors to downplay their results if they don’t conform with the official narrative regarding the COVID-19 vaccines. A study done in Iceland and published last summer found that double-vaccinated individuals were 42% more likely to become reinfected than others. But in their conclusions the authors called this just a “slightly higher” probability.

Now, a new study is out, published in the BMJ, that deals with female menstruation problems following vaccination. Nothing to worry about, according to mainstream media reporting. Indeed, in their conclusions the authors say:

Weak and inconsistent associations were observed between SARS-CoV-2 vaccination and healthcare contacts for bleeding in women who are postmenopausal, and even less evidence was recorded of an association for menstrual disturbance or bleeding in women who were premenopausal. These findings do not provide substantial support for a causal association between SARS-CoV-2 vaccination and healthcare contacts related to menstrual or bleeding disorders.

No reason to worry – really? Let’s take a look at the results section now:

2,580,007 (87.6%) of 2,946,448 women received at least one SARS-CoV-2 vaccination and 1,652,472 (64.0%) 2,580,007 of vaccinated women received three doses before the end of follow-up. The highest risks for bleeding in women who were postmenopausal were observed after the third dose, in the 1-7 days risk window (hazard ratio 1.28 (95% confidence interval 1.01 to 1.62)) and in the 8-90 days risk window (1.25 (1.04 to 1.50)). The impact of adjustment for covariates was modest. Risk of postmenopausal bleeding suggested a 23-33% increased risk after 8-90 days with BNT162b2 [Pfizer] and mRNA-1273 [Moderna] after the third dose, but the association with ChAdOx1 nCoV-19 [AstraZeneca] was less clear. For menstrual disturbance or bleeding in women who were premenopausal, adjustment for covariates almost completely removed the weak associations noted in the crude analyses.

So, actually significant risk for postmenopausal even after adjustments, but for premenopausal the “weak associations” were removed after adjustment for covariates. Why those huge adjustments? Before adjustment they found statistically significant increases of up to 44% – but that top figure was ‘adjusted’ away to just 4% (see Table 3). Yet even after these heroic adjustments there was still a 25% increase in menstrual disturbance following the first dose.